Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22702433 | 0.89 | CNR2 (0.42) | MAPTALDH1A1KMT2AMEN1CYP1A2 | |
| SCHEMBL18982556 | 0.86 | CNR2 (0.44) | ALDH1A1SMN1; SMN2KDM4ECNR2L3MBTL1 | |
| SCHEMBL16807989 | 0.86 | CNR2 (0.36) | KMT2AMEN1LMNACYP1A2SMN1; SMN2 | |
| SCHEMBL18982613 | 0.86 | ALDH1A1 (0.41) | MAPTALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL16796000 | 0.86 | ABCB11 (0.50) | MAPTALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL16795993 | 0.84 | SMN1; SMN2 (0.40) | MAPTALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL19616135 | 0.82 | CNR2 (0.44) | ALDH1A1SMN1; SMN2CNR2L3MBTL1 | |
| SCHEMBL16797513 | 0.81 | SMN1; SMN2 (0.36) | MAPTALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL18982146 | 0.80 | CYP1A2 (0.42) | ALDH1A1KMT2ALMNACYP1A2CYP2C9 | |
| SCHEMBL18982849 | 0.80 | MAPT (0.40) | MAPTALDH1A1LMNASMN1; SMN2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3310782-B1 | IMIDAZO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2021-12-01 | — | — | EP | disclosed |
| EP-3310782-B1 | IMIDAZO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2021-12-01 | — | — | EP | disclosed |
| EP-3303342-B1 | IMIDAZO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2021-03-17 | — | — | EP | disclosed |
| EP-3303342-B1 | IMIDAZO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2021-03-17 | — | — | EP | disclosed |
| US-10925876-B2 | Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders | MERCK SHARP & DOHME CORP. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10925876-B2 | Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders | MERCK SHARP & DOHME CORP. (US) | 2021-02-23 | — | — | US | disclosed |
| EP-3152214-B1 | IMIDAZO-PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2020-01-29 | — | — | EP | disclosed |
| EP-3152214-B1 | IMIDAZO-PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2020-01-29 | — | — | EP | disclosed |
| EP-3221319-B1 | TRIAZOLO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2019-10-30 | — | — | EP | disclosed |
| EP-3221319-B1 | TRIAZOLO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20170073355-A2 | TRIAZOLO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2017-03-16 | — | — | US | disclosed |
| US-20170073355-A2 | TRIAZOLO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2017-03-16 | — | — | US | disclosed |
| WO-2016191334-A1 | IMIDAZO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-01 | — | — | WO | disclosed |
| WO-2016191334-A1 | IMIDAZO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-01 | — | — | WO | disclosed |
| WO-2016191335-A1 | IMIDAZO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-01 | — | — | WO | disclosed |
| WO-2016191335-A1 | IMIDAZO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-01 | — | — | WO | disclosed |
| US-20160145272-A1 | TRIAZOLO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2016-05-26 | — | — | US | disclosed |
| US-20160145272-A1 | TRIAZOLO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2016-05-26 | — | — | US | disclosed |
| WO-2015187470-A1 | IMIDAZO-PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015187470-A1 | IMIDAZO-PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073355-A2 | TRIAZOLO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | PDE3A, PDE2A, PDE3B | MAPT 3915/4885ALDH1A1 1525/4885KMT2A 4660/4885 |
| US-20160145272-A1 | TRIAZOLO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | PDE3A, PDE2A, PDE3B | MAPT 3915/4885ALDH1A1 1525/4885KMT2A 4660/4885 |
| US-10925876-B2 | Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders | GUCY1B1, GUCY1A1, GUCY1A2 | MAPT 4783/4885ALDH1A1 1720/4885KMT2A 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.